Clinic
Baptist Health Deaconess Medical Group INC
Baptist Health Deaconess Medical Group INC was paid $1.14M by Medicaid between Sep 2021 and Dec 2024, across 36 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 37% of everything it billed.
33Billing provider infoBAPTIST HEALTH DEACONESS MEDICAL GROUP INC
POWDERLY, KY 42367
POWDERLY, KY 42367
33aNPI1558942011assigned 04/16/2021
33bProvider typeRural Health Clinic/Center
28Total paid$1.14M
24GClaims37,835
24DCodes billed36
24AFirst – last monthSep 2021 – Dec 2024
Compared with peers
Next to other Rural Health Clinic/Center providers in Kentucky
Rank by total paid#50 of 265
Median peer was paid$400K
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CLAY, DANYEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 3,939 | $82K | |
| 2022 | 13,903 | $390K | |
| 2023 | 12,318 | $371K | |
| 2024incomplete | 7,675 | $298K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 37% | 11,230 | 9,150 | $427K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 33% | 14,276 | 12,323 | $379K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 9.7% | 1,001 | 927 | $110K |
| 87428 | 4.8% | 1,385 | 1,317 | $55K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.9% | 2,555 | 2,352 | $33K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.1% | 385 | 375 | $24K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.6% | 875 | 842 | $18K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.5% | 360 | 325 | $17K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.3% | 722 | 571 | $15K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.0% | 212 | 196 | $12K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 1,177 | 875 | $12K |
| 99443 | <1% | 152 | 111 | $8K |
24 more codes
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 385 | $6K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 552 | $6K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 73 | $4K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 142 | $3K |
| 81025 | <1% | 434 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 113 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 44 | $2K |
| 77065 | Tomosynthesis, mammo | <1% | 27 | $1K |
| 76642 | <1% | 30 | $1K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 14 | $907.44 |
| 87210 | <1% | 283 | $904.64 | |
| 99442 | <1% | 36 | $855.61 | |
| 73630 | <1% | 66 | $716.30 | |
| 87807 | <1% | 57 | $617.56 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 137 | $520.26 |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $487.58 |
| 72100 | <1% | 33 | $483.75 | |
| 90686 | <1% | 35 | $329.60 | |
| 73610 | <1% | 14 | $187.33 | |
| 3008F | <1% | 326 | $0.22 | |
| 2014F | <1% | 290 | $0.17 | |
| 1160F | 0% | 194 | $0.00 | |
| 1159F | 0% | 194 | $0.00 | |
| 81003 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCLAY, DANYEL (EXECUTIVE DIRECTOR REVENUE CYCLE)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.